Dynavax downgraded by Goldman with a new price target
$DVAX
Biotechnology: Pharmaceutical Preparations
Health Care
Goldman downgraded Dynavax from Neutral to Sell and set a new price target of $12.00 from $15.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/11/2025 | $15.00 → $12.00 | Neutral → Sell | Goldman |
| 2/1/2024 | $20.00 | Neutral | Goldman |
| 9/27/2022 | $22.00 | Mkt Outperform | JMP Securities |
| 1/6/2022 | $38.00 | Buy | Goldman |
| 12/29/2021 | $23.00 → $28.00 | Buy | HC Wainwright & Co. |
| 8/31/2021 | $20.00 → $23.00 | Buy | HC Wainwright & Co. |
| 8/6/2021 | $19.00 | Buy | Goldman Sachs |
| 8/5/2021 | $16.00 → $20.00 | Buy | HC Wainwright & Co. |
EMERYVILLE, Calif., April 22, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2025 financial results on Tuesday, May 6, 2025, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Tuesday, May 6, 2025, at 4:30 p.m. ET/1:30 p.m. PT. The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynav
HEPLISAV-B® 2024 net product revenue grew 26% year-over-year to $268 million; net product revenue expected to be $305 to $325 million in 2025Top-line results in Phase 1/2 shingles trial expected in Q3 2025Plan to initiate Phase 2 trial for plague vaccine in Q3 2025Expect completion of $200 million share repurchase program in 2025Conference call today at 4:30 p.m. ET/1:30 p.m. PTEMERYVILLE, Calif., Feb. 20, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2024.
EMERYVILLE, Calif., Feb. 6, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Thursday, February 20, 2025, at 4:30 p.m. ET/1:30 p.m. PT. The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website
DEFC14A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)
DEFA14A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)
DEFC14A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)
SC 13G - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)
SC 13D/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)
SC 13G/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)
Urges Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card Highlights Record Financial and Operational Results, Balanced Capital Allocation Strategy andMeaningful Board Refreshment Underscores Deep Track's Value Destructive, Short-Term Focus and Unnecessary Proxy Contest EMERYVILLE, Calif., April 17, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that it has filed definitive proxy materials with the Securities and Exchange Commission ("SEC") in connection with its upcoming Annual Meeting of Stockhol
Salt Lake City, UT, March 18, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that Namandjé Bumpus, Ph.D, and Elaine Sun have been appointed to Recursion's Board of Directors, effective as of March 15th."I am delighted to welcome Elaine and Namandjé to Recursion's Board," said Chris Gibson, Ph.D., Recursion Co-Founder and CEO. "As the company continues to grow its clinical pipeline and enhance its platform, our new Board members' scientific, clinical, business and financial expertise will be an incredible resource in support of our continued success."Dr. Namandjé N. Bumpus served as the
Reiterates Meaningful Board Change Already Underway EMERYVILLE, Calif., Feb. 19, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today issued a statement underscoring continued execution momentum and commitment to driving long-term stockholder value. The Company also confirmed that Deep Track Capital ("Deep Track") has submitted a letter purporting to nominate four candidates to stand for election to the Dynavax Board of Directors at the Company's 2025 Annual Meeting of Stockholders.
EMERYVILLE, Calif., April 22, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2025 financial results on Tuesday, May 6, 2025, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Tuesday, May 6, 2025, at 4:30 p.m. ET/1:30 p.m. PT. The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynav
Believes Company's Misguided Acquisition Strategy is Destroying Value and Preventing Dynavax from Maximizing the Opportunities of Heplisav for Shareholders and Patients In Deep Track's View, Properly Focusing on Heplisav Could Result in More than $1 Billion in Cash Generation by 2030 – More than Dynavax's Current Enterprise Value Sees Shareholder Representation on Board as Necessary to Restore Investor Confidence in Dynavax and Prevent Strategic Blunders Urges Shareholders to Vote FOR Deep Track's Four Highly Qualified Director Nominees Deep Track Capital, LP, (together with its affiliates, "Deep Track" or "we"), one of the largest shareholders of Dynavax Technologies Corporation (NASDA
Urges Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card Highlights Record Financial and Operational Results, Balanced Capital Allocation Strategy andMeaningful Board Refreshment Underscores Deep Track's Value Destructive, Short-Term Focus and Unnecessary Proxy Contest EMERYVILLE, Calif., April 17, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that it has filed definitive proxy materials with the Securities and Exchange Commission ("SEC") in connection with its upcoming Annual Meeting of Stockhol
Goldman downgraded Dynavax from Neutral to Sell and set a new price target of $12.00 from $15.00 previously
Goldman initiated coverage of Dynavax with a rating of Neutral and set a new price target of $20.00
JMP Securities initiated coverage of Dynavax with a rating of Mkt Outperform and set a new price target of $22.00
4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)
4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)
4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)